↓ Skip to main content

Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis

Overview of attention for article published in Annals of Surgical Oncology, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
59 Dimensions

Readers on

mendeley
61 Mendeley
Title
Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis
Published in
Annals of Surgical Oncology, August 2015
DOI 10.1245/s10434-015-4779-6
Pubmed ID
Authors

C. Cabula, L. G. Campana, G. Grilz, S. Galuppo, R. Bussone, L. De Meo, A. Bonadies, P. Curatolo, M. De Laurentiis, M. Renne, S. Valpione, T. Fabrizio, N. Solari, M. Guida, A. Santoriello, M. D’Aiuto, R. Agresti

Abstract

The management of breast cancer (BC) skin metastases represents a therapeutic challenge. Electrochemotherapy (ECT) combines the administration of bleomycin with temporary permeabilization induced by locally administered electric pulses. Preliminary experience with ECT in BC patients is encouraging. A total of 125 patients with BC skin metastases who underwent ECT between 2010 and 2013 were enrolled onto a multicenter retrospective cohort study. The treatment was administered following the European Standard Operative Procedures of Electrochemotherapy. Tumor response was clinically assessed adapting the Response Evaluation Criteria in Solid Tumors, and toxicity was evaluated according to Common Terminology Criteria for Adverse Events 4.0. Cox regression analysis was used to identify predictive factors. Response was evaluable in 113 patients for 214 tumors (median 1 per patient, range 1-3). The overall response rate after 2 months was 90.2 %, while the complete response (CR) rate was 58.4 %. In multivariate analysis, small tumor size (P < 0.001), absence of visceral metastases (P = 0.001), estrogen receptor positivity (P = 0.016), and low Ki-67 index (P = 0.024) were significantly associated with CR. In the first 48 h, 10.4 % of patients reported severe skin pain. Dermatologic toxicity included grade 3 skin ulceration (8.0 %) and grade 2 skin hyperpigmentation (8.8 %). Tumor 1-year local progression-free survival was 86.2 % (95 % confidence interval 79.3-93.8) and 96.4 % (95 % confidence interval 91.6-100) in the subgroup of those with CR. In this study, small tumor size, absence of visceral metastases, estrogen receptor positivity, and low Ki-67 index were predictors of CR after ECT. Patients who experienced CR had durable local control. ECT represents a valuable skin-directed therapy for selected patients with BC.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 21%
Researcher 8 13%
Student > Bachelor 7 11%
Professor 5 8%
Other 4 7%
Other 11 18%
Unknown 13 21%
Readers by discipline Count As %
Medicine and Dentistry 18 30%
Biochemistry, Genetics and Molecular Biology 5 8%
Agricultural and Biological Sciences 4 7%
Veterinary Science and Veterinary Medicine 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Other 11 18%
Unknown 15 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2017.
All research outputs
#14,234,315
of 22,821,814 outputs
Outputs from Annals of Surgical Oncology
#4,060
of 6,465 outputs
Outputs of similar age
#136,056
of 264,147 outputs
Outputs of similar age from Annals of Surgical Oncology
#49
of 126 outputs
Altmetric has tracked 22,821,814 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,465 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,147 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 126 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.